PMID- 18465956
OWN - NLM
STAT- MEDLINE
DCOM- 20080820
LR  - 20211020
IS  - 1083-3668 (Print)
IS  - 1083-3668 (Linking)
VI  - 13
IP  - 2
DP  - 2008 Mar-Apr
TI  - Optical clearing of flowing blood using dextrans with spectral domain optical 
      coherence tomography.
PG  - 021107
LID - 10.1117/1.2909673 [doi]
AB  - Spectral domain optical coherence tomography (SDOCT) images have been used to 
      investigate the mechanism of optical clearing in flowing blood using dextrans. 
      The depth reflectivity profiles from SDOCT indicate that dextrans become 
      increasingly more effective in reducing scattering in flowing blood, except for 5 
      mgdl(-1) of Dx500, with increasing molecular weights (MW 70,000 and 500,000) and 
      concentrations (0.6, 2, and 5 mgdl(-1)). Among the tested dextrans, Dx500 at 2 
      mgdl(-1) had the most significant effect on light scattering reduction with the 
      strongest capability to induce erythrocyte aggregation. Dx500 at 5 mgdl(-1) 
      contributes more refractive index matching but induces a decrease in aggregation 
      that leads to the same level as 0.6 mgdl(-1) Dx500. Previous studies identified 
      various mechanisms of light scattering reduction in stationary blood induced by 
      optical clearing agents. Our results suggest that erythrocyte aggregation is a 
      more important mechanism for optical clearing in flowing blood using dextrans, 
      providing a rational design basis for effective flowing blood optical clearing, 
      which is essential for improving OCT imaging capability through flowing blood.
FAU - Xu, Xiangqun
AU  - Xu X
AD  - Zhejiang Sci-Tech University, School of Science, Hangzhou 310018, China. 
      xuxiangqun@zstu.edu.cn
FAU - Yu, Lingfeng
AU  - Yu L
FAU - Chen, Zhongping
AU  - Chen Z
LA  - eng
GR  - R01 EB000293-07/EB/NIBIB NIH HHS/United States
GR  - R01 CA091717-05/CA/NCI NIH HHS/United States
GR  - CA-91717/CA/NCI NIH HHS/United States
GR  - P41 RR001192-29/RR/NCRR NIH HHS/United States
GR  - P41 RR001192/RR/NCRR NIH HHS/United States
GR  - EB-00293/EB/NIBIB NIH HHS/United States
GR  - R01 EB000293/EB/NIBIB NIH HHS/United States
GR  - RR-01192/RR/NCRR NIH HHS/United States
GR  - R01 CA091717/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Biomed Opt
JT  - Journal of biomedical optics
JID - 9605853
RN  - 0 (Dextrans)
SB  - IM
MH  - Animals
MH  - Blood Flow Velocity/drug effects/*physiology
MH  - Blood Physiological Phenomena/*drug effects
MH  - Dextrans/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Mice
MH  - Muscle, Skeletal/*drug effects/*physiology
MH  - Refractometry
MH  - Swine
MH  - Tendons/*drug effects/*physiology
MH  - Tomography, Optical Coherence/*methods
PMC - PMC2778029
MID - NIHMS81442
EDAT- 2008/05/10 09:00
MHDA- 2008/08/21 09:00
PMCR- 2009/11/17
CRDT- 2008/05/10 09:00
PHST- 2008/05/10 09:00 [pubmed]
PHST- 2008/08/21 09:00 [medline]
PHST- 2008/05/10 09:00 [entrez]
PHST- 2009/11/17 00:00 [pmc-release]
AID - 10.1117/1.2909673 [doi]
PST - ppublish
SO  - J Biomed Opt. 2008 Mar-Apr;13(2):021107. doi: 10.1117/1.2909673.